Arguments for a lipid lowering therapy in coronary primary prevention;Lipidsenkende therapie zur primar-pravention der koronaren herzkrankheit - Pro lipidsenkende therapie

Zeitschrift fur Kardiologie

Volumn 87, Issue SUPPL. 2, 1998, Pages 205-209

  Steinmetz, A ^a   Noll, B ^a   Maisch, B ^a   Schafer J R ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Cholesterol; Coronary primary prevention; Lipid lowering

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CONFERENCE PAPER; CORONARY ARTERY DISEASE; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE; MORTALITY; PRIMARY PREVENTION; RISK FACTOR; SMOKING CESSATION; WEIGHT REDUCTION; BLOOD; REVIEW; TREATMENT OUTCOME;

ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; CORONARY DISEASE; HUMANS; HYPERCHOLESTEROLEMIA; RISK FACTORS; TREATMENT OUTCOME;

EID: 0031787377     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Assmann G, Schulte H (1986) PROCAM-Studie. Panscientia, Hedingen, Zürich
2. Cook RJ, Sackett DL (1995) The number to treat: a clinically useful measure of treatment effect. BMJ 310: 452-454
3. Cremer P, Nagel D, Labrot B, Muche R, Elster H, Mann H, Seidel D (1991) Göttinger Risiko-, Inzidenz- und Prävalenzstudie (GRIPS). Springer, Berlin, Heidelberg, New York
4. EAS Task Force for the Prevention of Coronary Heart Disease (1992) Prevention of coronary heart disease: scientific background, and new clinical guidelines. Nutr Metab Cardiovasc Dis 2: 113-156
5. Frick MH, Elo O, Haapa K, Heinommen P, Jeomsaö OP, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Nornola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA (1987) Helsinki heart study: primary prevention trial gemfibrocil in middle-aged men with dyslipemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237-1245
6. Grover SA, Coupal L, HuX-P (1995) Identifying adults at increased risk of coronary disease: how well do the current cholesterol guidelines work? JAMA 274: 801-806
7. Haq IU, Jackson PR, Yeo WW, Ramsay LE (1995) Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 346:1467-1471
8. Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H (Scandinavian Simvastatin Survival Study Group) (1997) Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 336: 332-336
9. Kronenberg F, Steinmetz A, Kostner GM, Dieplinger H (1996) Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci 33 (Suppl 6): 495-543
10. Lipid Research Clinics Program (1984a) The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251:351-364
11. Lipid Research Clinics Program (1984b) The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:365-374
12. Medical Research Council Working Party (1985) MRC trial of treatment of mild hypertension: principle results. BMJ 291: 97-104
13. Miller BD, Aldermann EL, Haskell WL, Fair JM, Krauss RM (1996) Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 94: 2146-2153
14. Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H, Pyörälä K, Miettinen T, Haghfelt T, Fægeman O, Thorgeirsson G, Jönsson B, Schwartz JS (Scandinavian Simvastatin Survival Study Group) (1996) Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 93: 1796-1802
15. Pharoah PDP, Hollingworth W (1996) Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 312: 1443-1448
16. Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN (1996) Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet 348: 387-388
17. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica J, Arnold JMO, Wun CC, Davis BR, Braunwald E (CARE Study Group) (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001-1009
18. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard C (West of Scotland Coronary Prevention Study Group) (1995) Prevention of coronary heart disease with Pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301-1307
19. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389
20. Steinmetz A, Maisch B, Noll B (1997) Auswirkungen lipidsenkender Maßnahmen auf die koronare Perfusion. Z Kardiol 86 (Suppl 1): 43-55
21. Strategies for the prevention of coronary heart disease (1987) Apolicy statement for the European Atherosclerosis Society. Eur Heart J 8: 77-88
22. West of Scotland Coronary Prevention Group (1996) West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 348: 1339-1342